NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $71,128 | $88,496 | $213,561 | $334,593 |
| - Cash | $58,815 | $51,476 | $53,271 | $67,549 |
| + Debt | $0 | $1,381 | $2,751 | $4,073 |
| Enterprise Value | $12,313 | $38,401 | $163,041 | $271,117 |
| Revenue | $165 | $582 | $1,423 | $2,247 |
| % Growth | -71.6% | -59.1% | -36.7% | – |
| Gross Profit | -$353 | $82 | $304 | $1,128 |
| % Margin | -213.9% | 14.1% | 21.4% | 50.2% |
| EBITDA | -$24,605 | -$30,496 | -$40,016 | -$50,194 |
| % Margin | -14,912.1% | -5,239.9% | -2,812.1% | -2,233.8% |
| Net Income | -$27,670 | -$28,797 | -$38,261 | -$45,100 |
| % Margin | -16,769.7% | -4,947.9% | -2,688.8% | -2,007.1% |
| EPS Diluted | -0.33 | -0.35 | -0.46 | -0.55 |
| % Growth | 5.7% | 23.9% | 16.4% | – |
| Operating Cash Flow | -$22,963 | -$27,164 | -$40,248 | -$41,827 |
| Capital Expenditures | -$188 | -$290 | -$104 | -$670 |
| Free Cash Flow | -$23,151 | -$27,454 | -$40,352 | -$42,497 |